Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting

NCT01949935 is registered in ClinicalTrials.gov with Horizon Health Network as lead sponsor.

NCT NCT01949935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting
Lead sponsor
Horizon Health Network
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
May 31, 2013
Enrollment
974 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

surgical site infections